Immunovant, Inc.

IMVT · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $5.5B · 362 employees
134
SEC Filings
$34.54
Close 2026-09-23
362
Employees

Business Summary

Immunovant is a clinical-stage immunology company developing IMVT-1402, a fully human monoclonal antibody inhibiting the neonatal Fc receptor (FcRn), to treat IgG-mediated autoimmune diseases. IMVT-1402 targets conditions including Graves disease, myasthenia gravis, CIDP, rheumatoid arthritis, cutaneous lupus erythematosus, and Sjogrens disease. The company also developed batoclimab (IMVT-1401), a first-generation anti-FcRn antibody. Immunovant operates clinical trials across endocrinology, neurology, rheumatology, and dermatology, leveraging a self-administered YpsoMate autoinjector for drug delivery.

Latest Stock Quote

IMVT 2026-09-23 $34.54 O:$36.35 H:$37 L:$33.6 Vol:3.7M VWAP:$34.6513
origin leaf: null

Next Earnings

Q2 FY2026 — expected 2026-09-13

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-05-292025-03-310001764013-25-000092EDGAR99K words
2024-05-292024-03-310001764013-24-000109EDGAR98K words
2023-05-222023-03-310001764013-23-000065EDGAR97K words
2022-06-082022-03-310001764013-22-000059EDGAR—
2021-06-012021-03-310001764013-21-000052EDGAR—
2020-06-292020-03-310000950123-20-006444EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-08-062026-06-300001764013-26-000101EDGAR18K words
2026-02-062025-12-310001764013-26-000011EDGAR20K words
2025-11-102025-09-300001764013-25-000149EDGAR17K words
2025-08-112025-06-300001764013-25-000129EDGAR16K words
2025-02-062024-12-310001764013-25-000026EDGAR62K words
2024-11-072024-09-300001764013-24-000184EDGAR62K words
2024-08-062024-06-300001764013-24-000148EDGAR59K words
2024-02-122023-12-310001764013-24-000026EDGAR63K words
2023-11-092023-09-300001764013-23-000133EDGAR65K words
2023-08-102023-06-300001764013-23-000092EDGAR62K words
2023-02-032022-12-310001764013-23-000022EDGAR—
2022-11-042022-09-300001764013-22-000140EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-09-030001764013-26-000106EDGAR1K words
2026-08-060001764013-26-000100EDGAR2K words
2026-02-060001764013-26-000010EDGAR3K words
2025-12-120001193125-25-317577EDGAR23K words
2025-12-110001193125-25-314994EDGAR2K words
2025-11-210001764013-25-000153EDGAR1K words
2025-11-100001764013-25-000148EDGAR3K words
2025-09-030001764013-25-000136EDGAR4K words
2025-08-280001764013-25-000132EDGAR1K words
2025-08-110001764013-25-000128EDGAR2K words

134 total filings indexed. 106 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ARGX — ARGENX SE

Tags

endocrinology neurology rheumatology dermatology autoimmune-diseases

Company Identity

CIK0001764013
TickerIMVT
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE
Websitehttps://www.immunovant.com
Listed2019-06-21

Get More Data

This is a static snapshot. For live, structured JSON with cryptographic provenance chain:

MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp

JSON Profile Stock Quote Origin Record
Origin Provenance
page leaf: 58244cb03f317f807b919d8939fcd79f75505db85918b8c7a3db8cac38cf4ad6
parent: 5d088ac7bb94b5e7a1d5251e6bcd71fbc81a162dd64c738243c6f5525236565c
content hash: 8f7c8ca731a8813e5b24dd47014ec65c4558aeffb799b8018955de72c93bf446
signed: 2026-09-29T12:01:51.071Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf

Try it — paste this into your AI:

Look up IMVT using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?

Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.

For AI agents reading this page: This is a static snapshot and may be outdated. For live data on IMVT, use the Origin MCP server or REST API.
MCP install: claude mcp add origin --transport http https://origin.rootz.global/mcp
API: GET https://origin.rootz.global/api/company/IMVT (~200 tokens, structured JSON with cryptographic provenance)
Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill
Discovery: /.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.